Beginning Cash (Annual)

Beginning Cash: The amount of cash reported by the company on its previous statement.

AstraZeneca PLC (AZN) had Beginning Cash of $5.43B for the most recently reported fiscal year, ending 2025-12-31.

Quarterly Annual

Figures for fiscal year ending 2025-12-31

Income Statement Financials
Revenue	$58.74B
Net Income	$10.22B
Cost of Goods Sold	$10.63B
Gross Profit	$48.11B
Operating Expenses	$45.00B
Operating Income	$13.74B
Non-Operating Income/Expense	$-1.34B
Pre-Tax Income	$12.40B
Normalized Pre-Tax Income	$12.40B
Income after Taxes	$10.23B
Income from Continuous Operations	$10.23B
Consolidated Net Income/Loss	$10.23B
Normalized Income after Taxes	$10.23B
EBIT	$13.74B
EBITDA	$19.48B
Weighted-Average Shares Outstanding (Basic)	3.10B
Weighted-Average Shares Outstanding (Diluted)	3.12B
Earnings per Share (EPS) (Basic)	$3.30
Earnings per Share (EPS) (Diluted)	$3.27
Balance Sheet Financials
Current Assets	$28.72B
Property, Plant, and Equipment	$12.96B
Long-Term Assets	$85.35B
Total Assets	$114.07B
Current Liabilities	$30.62B
Long-Term Debt	$24.71B
Long-Term Liabilities	$34.74B
Total Liabilities	$65.36B
Common Equity	$48.72B
Tangible Shareholders Equity	$-10.37B
Shareholders Equity	$48.72B
Common Shares Outstanding	3.10B
Cash Flow Statement Financials
Cash Flow from Operating Activities	$14.57B
Cash Flow from Investing Activities	$-6.81B
Cash Flow from Financial Activities	$-7.54B
Beginning Cash	$5.43B
End Cash	$5.70B
Increase/Decrease in Cash	$269.00M
Stock-Based Compensation	--
Common Stock Dividends Paid	$-4.97B
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	0.94
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.34
Debt to Equity Ratio	0.57
Gross Margin	81.90%
Operating Margin	23.40%
EBIT Margin	23.40%
EBITDA Margin	33.16%
Pre-Tax Profit Margin	21.11%
Profit Margin	17.41%
Free Cash Flow	$11.78B
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.51
Inventory Turnover	1.62
Receiveable Turnover	3.60
Days Sales in Receivables	101.50
Return on Equity	21.00%
Return on Tangible Equity	-98.69%
Return on Assets	8.97%
Return on Investments	13.94%
Book Value Per Share	$15.71
Free Cash Flow per Share	$3.77
Operating Cash Flow per Share	$4.67

Data from Zacks Investment Research, Inc.